Artelo Biosciences Reports Q3 Results, Talks Patent For Cocrystal CBD
Artelo Biosciences (NASDAQ: ARTL) announced its third-quarter results as of May 31.
The La Jolla, California-based company reported a net loss of $951,191, approximately $0.27 per basic share in contrast to $0.17 per share for the same quarter 2019.